These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7551591)

  • 1. Economics of treatment of depression.
    Owens DW
    Br J Psychiatry; 1995 Jul; 167(1):112. PubMed ID: 7551591
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost analysis of paroxetine versus imipramine in major depression.
    Bentkover JD; Feighner JP
    Pharmacoeconomics; 1995 Sep; 8(3):223-32. PubMed ID: 10155618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct cost of depression: analysis of treatment costs of paroxetine versus Imipramine in Canada.
    Lapierre Y; Bentkover J; Schainbaum S; Manners S
    Can J Psychiatry; 1995 Sep; 40(7):370-7. PubMed ID: 8548716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation of paroxetine and imipramine in depressed outpatients.
    Melton ST; Kirkwood CK; Farrar TW; Brink DD; Carroll NV
    Psychopharmacol Bull; 1997; 33(1):93-100. PubMed ID: 9133757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economics of treatment of depression.
    Freemantle N; House A; Mason J; Song F; Sheldon T
    Br J Psychiatry; 1995 Mar; 166(3):397-9. PubMed ID: 7788136
    [No Abstract]   [Full Text] [Related]  

  • 6. Economic analysis of treating depression with nefazodone v. imipramine.
    Montgomery SA; Brown RE; Clark M
    Br J Psychiatry; 1996 Jun; 168(6):768-71. PubMed ID: 8773822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-efficacy of individual and combined treatments for panic disorder.
    McHugh RK; Otto MW; Barlow DH; Gorman JM; Shear MK; Woods SW
    J Clin Psychiatry; 2007 Jul; 68(7):1038-44. PubMed ID: 17685740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of antidepressants.
    O'Brien JT
    Br J Psychiatry; 1994 Sep; 165(3):411-2. PubMed ID: 7864978
    [No Abstract]   [Full Text] [Related]  

  • 9. Economic appraisal of citalopram in the management of single-episode depression.
    Sclar DA; Skaer TL; Robison LM; Galin RS
    J Clin Psychopharmacol; 1999 Oct; 19(5 Suppl 1):47S-54S. PubMed ID: 10507508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of treatment resistance on depressive relapse following electroconvulsive therapy.
    Flint A
    Acta Psychiatr Scand; 1997 Nov; 96(5):405-6. PubMed ID: 9395161
    [No Abstract]   [Full Text] [Related]  

  • 11. Paroxetine. A pharmacoeconomic evaluation of its use in depression.
    Wilde MI; Whittington R
    Pharmacoeconomics; 1995 Jul; 8(1):62-81. PubMed ID: 10155603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antidepressant response follows an exponential decay curve: replication and extension.
    Boyer W
    J Clin Psychopharmacol; 1997 Oct; 17(5):426-7. PubMed ID: 9315997
    [No Abstract]   [Full Text] [Related]  

  • 13. Fluoxetine and imipramine: are there differences in cost-utility for depression in primary care?
    Serrano-Blanco A; Suárez D; Pinto-Meza A; Peñarrubia MT; Haro JM;
    J Eval Clin Pract; 2009 Feb; 15(1):195-203. PubMed ID: 19239602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic comparisons of the pharmacotherapy of depression: an overview.
    Crott R; Gilis P
    Acta Psychiatr Scand; 1998 Apr; 97(4):241-52. PubMed ID: 9570483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment.
    Jönsson B; Bebbington PE
    Br J Psychiatry; 1994 May; 164(5):665-73. PubMed ID: 7921718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-benefit analysis of newer versus older antidepressants--pharmacoeconomic studies comparing SSRIs/SNRIs with tricyclic antidepressants.
    Laux G
    Pharmacopsychiatry; 2001 Jan; 34(1):1-5. PubMed ID: 11229615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Something rotten in the state of clinical and economic evaluations?
    Freemantle N; Maynard A
    Health Econ; 1994; 3(2):63-7. PubMed ID: 7880237
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-effectiveness of psychological and pharmacological interventions for generalized anxiety disorder and panic disorder.
    Heuzenroeder L; Donnelly M; Haby MM; Mihalopoulos C; Rossell R; Carter R; Andrews G; Vos T
    Aust N Z J Psychiatry; 2004 Aug; 38(8):602-12. PubMed ID: 15298582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressants.
    Simon GE; VonKorff M; Heiligenstein JH; Revicki DA; Grothaus L; Katon W; Wagner EH
    JAMA; 1996 Jun; 275(24):1897-902. PubMed ID: 8648870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TCAs or SSRIs as initial therapy for depression?
    Tyra JM; Greenawald MH
    J Fam Pract; 1999 Nov; 48(11):845-6. PubMed ID: 10907616
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.